Boehringer Wins Europe’s First Biosimilar Approval

Boehringer Ingelheim has been granted its first biosimilar approval in Europe...
Boehringer Ingelheim has been granted its first biosimilar approval in Europe (c) Alexander Raths/Shutterstock

Boehringer Ingelheim has been granted its first biosimilar approval in Europe, receiving  authorization to market Cyltezo for treating a variety of chronic inflammatory diseases in adults, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Cyltezo is a biosimilar of AbbVie’s Humira, a monoclonal antibody that generates annual sales of around $15 billion. Biosimilar versions are expected to be significantly cheaper than their expensive biologic counterparts, potentially saving substantial sums for healthcare providers.

Ivan Blanarik, senior vice president and head of therapeutic area biosimilars at Boehringer Ingelheim, said the approval marks a significant step forward for offering effective and more affordable treatment options for patients with chronic inflammatory diseases. “We believe biosimilars will be a key contributor to the future sustainability of healthcare systems around the world.”

According to the German producer, the drug’s approval, which also covers certain pediatric inflammatory diseases, was based on a comprehensive data package supporting the biosimilarity of Cyltezo to Humira and comprising analytical, pharmacological, non-clinical and clinical data.

However, Boehringer Ingelheim said it does not intend to make Cyltezo commercially available in Europe until the respective supplementary protection certificate (SPC) for Humira expires in October 2018. An SPC extends the duration of certain rights associated with a patent.

Cyltezo was also approved in the US in late August, just a few weeks after AbbVie filed suit against Boehringer in a Delaware federal court. AbbVie is reported to hold more than 100 patents on Humira with the likelihood that the German drugmaker could infringe 74 of them with its biosimilar version.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.